Clement Chung - Hematology/Oncology clinical pharmacist specialist

Clement Chung

Hematology/Oncology clinical pharmacist specialist

United States

Main Specialties: Oncology

Additional Specialties: Hematology, Oncology

ORCID logohttps://orcid.org/0000-0002-7189-6612

Clement Chung - Hematology/Oncology clinical pharmacist specialist

Clement Chung

Education

Sep 1997 - Mar 2001
University of Washington
Pharm.D.
School of Pharmacy

Publications

29Publications

270Reads

2174Profile Views

37PubMed Central Citations

Restoring the switch for cancer cell death: Targeting the apoptosis signaling pathway.

Authors:
Clement Chung

Am J Health Syst Pharm 2018 Jul 14;75(13):945-952. Epub 2018 May 14.

Lyndon B. Johnson General Hospital, Houston, TX

View Article

Download full-text PDF

Source
http://www.ajhp.org/lookup/doi/10.2146/ajhp170607
Publisher Site
http://dx.doi.org/10.2146/ajhp170607DOI Listing
July 2018
7 Reads
2.210 Impact Factor

Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet?

Pharmacotherapy 2017 Sep 31;37(9):1052-1072. Epub 2017 Jul 31.

MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/phar.1977DOI Listing
September 2017
45 Reads
2.662 Impact Factor

Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.

Authors:
Clement Chung

J Oncol Pharm Pract 2016 Jun 8;22(3):461-76. Epub 2015 Apr 8.

Hematology/Oncology Clinical Pharmacist Specialist, Lyndon B Johnson General Hospital, Harris Health System, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155215577810DOI Listing
June 2016
14 Reads
10 Citations

Importance of ethnicity and smoking status in EGFR gene testing in lung cancers.

Authors:
Clement Chung

Am J Health Syst Pharm 2015 May;72(9):686

Lyndon B. Johnson General HospitalHarris Health SystemHouston,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2146/ajhp140856DOI Listing
May 2015
10 Reads
2.210 Impact Factor

Trametinib: A novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma.

Authors:
Chung C Reilly S.

Am J Health Syst Pharm. 2015 Jan 15;72(2):101-110

Am J Health Syst Pharm

PURPOSE: The pharmacology, pharmacokinetics, clinical efficacy, safety, administration, cost, and place in therapy of trametinib for the treatment of metastatic melanoma are reviewed. SUMMARY: Approximately 40-60% of malignant melanomas have gene mutations at codon 600 of the BRAF gene that result in the activation of the mitogen-activated protein kinase (MAPK) pathway. Trametinib is the first-in-class mitogen-activated, extracellular signal-regulated kinase (MEK) inhibitor that targets a kinase in the MAPK pathway that plays a key role in oncogenic cell proliferation, survival, invasion, tumor angiogenesis, and escape from apoptosis. It is approved by the Food and Drug Administration for use in patients whose tumors express the BRAF V600E or V600K gene mutations. Moreover, trametinib is also indicated for use in combination with dabrafenib (a BRAF inhibitor). Trametinib is not indicated in patients who have received prior BRAF-inhibitor therapy due to poor response and possible cross-resistance. The most common adverse effects associated with the use of trametinib for both monotherapy and combination therapy are rash, diarrhea, peripheral edema, fatigue, and dermatitis. The recommended dosage of trametinib monotherapy is 2 mg orally once daily until disease progression or unacceptable toxicity occurs. With a daily dose of 2 mg, an estimated 30-day course of treatment would cost approximately $9135. CONCLUSION: Trametinib, a novel MEK inhibitor, provides an alternative therapy for patients with BRAF V600 E/K metastatic melanoma as a single agent or in combination therapy for patients not previously treated with a BRAF inhibitor. More studies are needed to determine the safe and effective combination or sequencing of trametinib with other therapies.

View Article
January 2015
14 Reads

Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia.

Pharmacotherapy 2014 Dec 30;34(12):1298-316. Epub 2014 Oct 30.

Lyndon B. Johnson General Hospital, Harris Health System, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/phar.1509DOI Listing
December 2014
36 Reads
3 Citations
2.662 Impact Factor

Omacetaxine for treatment-resistant or treatment-intolerant adult chronic myeloid leukemia.

Authors:
Clement Chung

Am J Health Syst Pharm 2014 Feb;71(4):279-88

Clement Chung, Pharm.D., BCOP, BCPS, is Oncology Clinical Pharmacist, Lyndon B. Johnson General Hospital, Harris Health System, Houston, TX

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2146/ajhp130506DOI Listing
February 2014
13 Reads
1 Citation
2.210 Impact Factor

Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation.

J Oncol Pharm Pract 2014 Feb 14;20(1):11-28. Epub 2013 Mar 14.

Department of Pharmacy, Kennewick General Hospital, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155212474047DOI Listing
February 2014
14 Reads
15 Citations

Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer.

Am J Health Syst Pharm 2013 Nov;70(21):1887-96

Clement Chung, Pharm.D., BCOP, BCPS, is Oncology Clinical Pharmacist, Lyndon B. Johnson General Hospital, Harris Health System, Houston, TX. Nisha Pherwani, Pharm.D., BCOP, is Clinical Director, Oncology, Cardinal Health Pharmacy Solutions, Houston, TX 77077.

View Article

Download full-text PDF

Source
http://www.ajhp.org/cgi/doi/10.2146/ajhp130143
Publisher Site
http://dx.doi.org/10.2146/ajhp130143DOI Listing
November 2013
30 Reads
4 Citations
2.210 Impact Factor

Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.

Am J Health Syst Pharm 2013 Sep;70(18):1579-87

Department of Pharmacy, Lyndon B. Johnson General Hospital, Harris Health System, Houston, TX 77026, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2146/ajhp120735DOI Listing
September 2013
63 Reads
3 Citations
2.210 Impact Factor

Development and implementation of an interdisciplinary oncology program in a community hospital.

Am J Health Syst Pharm 2011 Sep;68(18):1740-7

Valley Medical Center, Renton, WA 98055, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2146/ajhp100626DOI Listing
September 2011
38 Reads
1 Citation
2.210 Impact Factor

Top co-authors

Angela Collins
Angela Collins

Capstone College of Nursing

1
Matthew Christianson
Matthew Christianson

Group Health Research Institute; University of Washington; and Group Health Cooperative

1
Masha S H Lam
Masha S H Lam

University of California-Irvine

1
Nisha Pherwani
Nisha Pherwani

is Clinical Director

1
Hilary Ma
Hilary Ma

National Cancer Institute

1